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Dear Editor, 
 We read the article by Papamichael et al. with interest.1 This was a retrospective 
cohort study comparing the long-term outcomes of inflammatory bowel disease (IBD) 
patients treated with infliximab. The authors concluded that proactive therapeutic drug 
monitoring (TDM) was associated with better clinical outcomes including greater drug 
durability, less need for IBD-related surgery or hospitalization, and a lower risk of 
developing antibodies to infliximab than those in whom TDM was reactive. However, there 
are some issues with the study design that we would like to draw attention to.  
 Reactive TDM was performed only in patients who presented with symptoms 
consistent with current disease activity, or those who had experienced a prior infusion 
reaction. Thus, the apparent association of proactive TDM with improved clinical disease 
outcomes is likely to be largely related to the disparity in disease activity between patients in 
the proactive and reactive TDM groups at study entry. Although the authors acknowledge this 
as a limitation, they did not provide data on disease activity at the time of first institution of 
TDM.  
In addition, the proportion of patients receiving escalated dosing of infliximab at the 
time of inclusion in the study was significantly higher in the reactive TDM group (51% vs. 
35%; P = 0.009), again suggesting a significant difference in inflammatory activity between 
the two groups. Furthermore, at the time of allocation to proactive versus reactive TDM, 
antibodies to infliximab were present in a significantly higher proportion of patients in the 
reactive versus the proactive groups (28% versus 5%), which is likely to explain the 
increased risk of subsequent infusion reaction seen in this group of patients, as has been 
described previously.2 
 The TAXIT study was a randomized controlled trial assessing the impact of TDM in 
infliximab treated IBD patients.3 In this study, infliximab responders with optimized 
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infliximab trough levels were randomized to a dosing regimen based only on physician's 
assessment of clinical disease activity, or a group where dosing was based on TDM. There 
was no difference in clinical and biological remission between the two groups after 12 
months of therapy, but the proportion of patients flaring during the maintenance phase of the 
study was lower in those with TDM-based infliximab dosing. These findings indicate that 
Papamichael et al. are likely to have overestimated the superiority of proactive over reactive 
TDM on clinical outcomes in IBD. 
 Optimization of anti-TNF therapy may be associated with improved outcomes in 
IBD,4 and further studies investigating how better to personalize these treatments are 
welcome.5 Proactive TDM is the logical approach to the long-term management of patients 
treated with infliximab but, on the basis of the findings of the current study, its superiority 
over reactive TDM cannot be ascertained.  
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